OpenAlex
PricingAboutJobs
Log inGet started
Work

FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1

HTML

Year: 2020
Type: article
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-19-3545
Authors: Preeti Narayan, Sakar Wahby, Jennifer J. Gao, Laleh Amiri-Kordestani, Amna Ibrahim, Erik Bloomquist, Shenghui Tang, Yuan Xu, Jiang Liu, Wentao Fu, Pengfei Song, Bellinda L. King-Kallimanis, Sherry Hou, Yutao Gong, Shyam Kalavar, Soma Ghosh, Reena Philip, Kirsten B. Goldberg, Marc R. Theoret, Gideon M. Blumenthal, Paul G. Kluetz, Rajeshwari Sridhara, Richard Pazdur, Julia A. Beaver
Institutions: United States Food and Drug Administration, Center for Drug Evaluation and Research, Center for Devices and Radiological Health
Language: English

Topic: Cancer Immunotherapy and Biomarkers
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: atezolizumab, triple-negative breast cancer, PD-L1 expression, immune checkpoint inhibitors, metastatic breast cancer, progression-free survival, overall survival, accelerated approval, adverse events
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W3003627105
FWCI: 11.99
Cites: 9
Cited by: 191
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security